Abstracts tagged "Lupus and systemic lupus erythematosus (SLE)"

Abstract Number: 784 • 2016 ACR/ARHP Annual Meeting
Drivers of the SLE Responder Index (SRI) Endpoint in Clinical Trials of SLE
Kenneth C. Kalunian¹, Murray Urowitz², David A. Isenberg³, Joan T. Merrill⁴, Michelle Petri⁵, Richard Furie⁶, MaryAnn Morgan-Cox⁷, Rebecca Taha⁷, Maria Silk⁷ and Matthew D Linnik⁸, ¹Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ²Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶North Shore University Hospital, Great Neck, NY, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Immunology, Lilly Biotechnology Center, San Diego, CA
Background/Purpose: SRI is a composite endpoint designed to ensure that clinical improvement (measured by SLEDAI) is not accompanied by deterioration in other organ systems (measured…
Abstract Number: 1246 • 2016 ACR/ARHP Annual Meeting
Causes and Predictors of Early Readmission in Systemic Lupus Erythematosus
Angelica Nangit¹, Michael Weisman², Mariko Ishimori², Brennan Spiegel³ and Connie Lin⁴, ¹Rheumatology, Cedars Sinai Medical Center, Reseda, CA, ²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Gastroenterology; Health Policy and Management, Cedars-Sinai Health System and UCLA School of Medicine and Public Health, Los Angeles, CA, ⁴Internal Medicine, Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose : Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is largely heterogeneous and can affect virtually any organ system. Each year about…
Abstract Number: 1238 • 2015 ACR/ARHP Annual Meeting
Incident Systemic Lupus Erythematosus in Males in a Northern California County Hospital
Jorge A. Uribe¹, Julia F Simard², Laura Tarter³ and Thomas M. Bush¹, ¹Medicine/Rheumatology, Santa Clara Valley Medical Center, San Jose, CA, ²Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ³Rheumatology, Stanford University Hospital, Stanford, CA
Background/Purpose: Little is known about males with systemic lupus erythematosus (SLE), particularly among those with a recent diagnosis. To better understand the presentation and outcomes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].